Monitor for any subsequent increase in institutional ownership or trading volume as a result of the enhanced visibility from the uplisting. The next catalyst is the Phase 3 DRAGON II and PHOENIX trial data readouts.
Price Chart
Executive Summary
Belite Bio announced it has received approval to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026, under the same ticker 'BLTE'. The uplisting to the highest Nasdaq tier reflects compliance with more stringent financial and liquidity standards and is expected to enhance institutional visibility, liquidity, and market recognition.
Key Facts
- Belite Bio received approval from Nasdaq to transfer its listing from the Nasdaq Capital Market to the Nasdaq Global Select Market.
- Trading on the Nasdaq Global Select Market commenced at the open of market on October 19, 2026.
- The company retains its existing ticker symbol 'BLTE'.
- The Nasdaq Global Select Market is the highest of the three Nasdaq market tiers.
- The uplisting reflects compliance with more stringent financial and liquidity standards.
Financial Impact
No financial figures provided in the filing; uplisting is a structural change with no immediate financial impact.
Risk Factors
- Uplisting does not change the company's clinical-stage risk profile or the need for regulatory approval of tinlarebant.
- No financial data or guidance was provided in this filing.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-116685 |
| Document: tm2627719d1_ex99-1.htm | 0001104659-26-116685 |
| Document: 0001104659-26-116685-index-headers.html | 0001104659-26-116685 |
| Document: 0001104659-26-116685-index.html | 0001104659-26-116685 |
| Document: 0001104659-26-116685.txt | 0001104659-26-116685 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $147.34 | awaiting T+20 | — | $147.33 (−0.01%) |
Sep 9, 2026 6w ago | Insider Cluster | $175.07 $152.52 | ▲ +12.88% | ▲ +15.01% | $147.33 (+15.85%) |
Aug 12, 2026 10w ago | 6-K | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Aug 12, 2026 10w ago | Press Release | $166.28 $173.79 | ▲ +4.52% | ▲ +6.26% | $147.33 (−11.40%) |
Jun 12, 2026 19w ago | 6-K | $144.24 $147.03 | ▲ +1.93% | ▲ +2.68% | $147.33 (+2.14%) |
May 20, 2026 22w ago | Press Release | $143.36 $146.12 | ▲ +1.93% | ▲ +1.18% | $147.33 (+2.77%) |
Apr 21, 2026 26w ago | 6-K | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 21, 2026 26w ago | Press Release | $167.42 $139.70 | ▼ −16.56% | ▼ −19.72% | $147.33 (−12.00%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
Apr 9, 2026 28w ago | Insider Cluster | $181.17 $156.21 | ▲ +13.78% | ▲ +21.34% | $147.33 (+18.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers